Form 4 Centessa Pharmaceuticals For: Sep 20 Filed by: SAHA SAURABH
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $27.00 price target on the stock.MarketBeat
- Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual MeetingGlobeNewswire
- Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical OfficerGlobeNewswire
CNTA
Earnings
- 11/12/24 - Beat
CNTA
Sec Filings
- 2/26/25 - Form 4
- 2/25/25 - Form 144
- 2/21/25 - Form 8-K
- CNTA's page on the SEC website